This page presents the investment thesis, operating model, growth plan and risks. The financial model, pricing, grants, costs, margins and scenarios are managed in the dashboard as the single source of truth.
Selvese Botanica
Executive Summary · 2026–2031
The model’s operating spine and critical figures at a glance.
Selvese is building a premium botanical-processing model priced on quality rather than agricultural volume. Revenue is diversified across essential oils, extracts and hydrosols. Capital is concentrated in the quality backbone, while scale depends on the contract-grower network.
The strategy page explains the investment thesis and why the model exists. Revenue, EBITDA, net profit, grants, investment phases, costs, raw-material margins and scenario controls are tracked in the dashboard as the single canonical source, avoiding duplicate financial figures across pages.
SELVESE BOTANICA · 20 PRODUCTS · B2B · ESSENTIAL OIL · HYDROSOL · STANDARDIZED EXTRACT
Selvese Botanica
Section 2 & 3 — Vision, Team and Market Analysis · 2026–2031
The central facility planned in Eskisehir Redins converts raw material from contracted manufacturer network into standardized active component — distilation, extraction and quality laboratory under one roof.
SELVESE BOTANICA · SECTION 5 · 2026–2031
| Products | ethanol Rate | Ethanol : Water | Target Active Component | Format |
|---|---|---|---|---|
| Ekinezya | %70 | Alkamides, cichoric acid | Liquid + Dry powder | |
| St John’s Wort | %60 | Hypericin, hyperforin | Liquid + Dry powder | |
| Tags | %70 | OPC, vitexin, hyperoside | Dry powder | |
| Rodiola | %60 | Rosavin, salidroside | Liquid + Dry powder | |
| Licorice Root | %30 | Glycyrrhizin, liquiritin | Dry powder | |
| Marshmallow Root | Water based | Contractor, Polysaccharides | Liquid extra Tags | |
| Otu | %50 | Triterpenoid saponins | Dry powder |
SELVESE BOTANICA · SECTION 7 · TURKEY + EUROPE · 2026–2035
TEK KANONIK RESOURCE · DASHBOARD · INVESTMENT · HIBE · P&L · MARJ
Income projection, EBITDA, net profit, investment phases, IPARD / TUBITAK / KOSGEB support assumptions, head analysis, cash flow, product-based income distribution, raw material cost and margin account are kept in dashboard as single quantitative source. The strategy document shows that only the financial model responds to what decision questions.
Not to produce Rakam, which figure feeds what strategic decision.
The central facility is monitored in the dashboard where analytical spine and scale phases need capital. The decision principle on the strategy remains constant: not aggressive debt, but with the combination of cash flow and appropriate grants.
Return increase is tested with product form and capacity growth dashboard scenarios. This page only states that the quality standard will not grow volume without protection.
Price fluctuation, buyer condensation, raw material cost and margin printing are digitized in the dashboard; it is interpreted as risk discipline in the strategy section.
SELVESE BOTANICA · SECTION 8 · 11 RISK · 5 CATEGORY · MITGATION + ACID PLAN